Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.45 Insider Own6.50% Shs Outstand54.81M Perf Week-2.21%
Market Cap1.63B Forward P/E- EPS next Y-1.72 Insider Trans-2.32% Shs Float51.19M Perf Month-2.30%
Income-267.30M PEG- EPS next Q-0.45 Inst Own72.70% Short Float18.61% Perf Quarter0.13%
Sales5.40M P/S301.25 EPS this Y-5.50% Inst Trans-5.97% Short Ratio3.71 Perf Half Y-47.21%
Book/sh6.16 P/B4.82 EPS next Y27.40% ROA-80.50% Target Price60.78 Perf Year62.10%
Cash/sh5.80 P/C5.12 EPS next 5Y-0.20% ROE-106.30% 52W Range8.00 - 63.73 Perf YTD8.20%
Dividend- P/FCF- EPS past 5Y- ROI-75.60% 52W High-53.43% Beta1.60
Dividend %- Quick Ratio4.80 Sales past 5Y-35.10% Gross Margin97.60% 52W Low271.00% ATR1.67
Employees197 Current Ratio5.00 Sales Q/Q315.40% Oper. Margin- RSI (14)45.16 Volatility4.62% 5.85%
OptionableYes Debt/Eq0.05 EPS Q/Q-12.30% Profit Margin- Rel Volume0.40 Prev Close30.19
ShortableYes LT Debt/Eq0.02 EarningsFeb 28 AMC Payout- Avg Volume2.57M Price29.68
Recom1.90 SMA20-5.96% SMA50-5.04% SMA200-8.81% Volume1,036,650 Change-1.69%
Mar-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Mar-02-17Initiated Instinet Buy $84
Mar-01-17Reiterated RBC Capital Mkts Outperform $98 → $91
Feb-22-17Reiterated Needham Buy $81 → $78
Jan-04-17Reiterated Morgan Stanley Equal-Weight $53 → $33
Dec-22-16Initiated JP Morgan Overweight $40
Dec-20-16Initiated Goldman Neutral
Dec-16-16Reiterated RBC Capital Mkts Outperform $106 → $98
Dec-14-16Reiterated Jefferies Hold $46 → $32
Oct-28-16Reiterated RBC Capital Mkts Outperform $108 → $106
Oct-27-16Initiated Morgan Stanley Equal-Weight $53
Oct-18-16Initiated Credit Suisse Outperform $68
Oct-10-16Reiterated Wedbush Outperform $66 → $72
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Sep-19-16Reiterated Robert W. Baird Outperform $23 → $102
Jul-22-16Reiterated Needham Buy $20 → $26
Jun-09-16Upgrade Piper Jaffray Underweight → Neutral
Mar-22-17 01:06PM  Market Is Home on the Range Again
Mar-17-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics Accesswire
08:30AM  Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference GlobeNewswire
08:16AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : March 17, 2017
Mar-16-17 04:40PM  Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought at MarketWatch
03:33PM  PTC Therapeutics Buys Duchenne Drug for $140M at Investopedia
Mar-13-17 09:32AM  Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
Mar-10-17 05:57PM  Trump nominates FDA head with deep ties to drug companies Reuters
03:21PM  Payor Re-Evaluation On Exondys Positive For Sarepta
02:33PM  Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease
Mar-07-17 06:48AM  Vetr Advises Hold On Sarepta
Mar-04-17 01:04PM  SAREPTA THERAPEUTICS, INC. Financials
Mar-03-17 11:54AM  Market Action Is Boring but Necessary +5.39%
11:11AM  2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump at Motley Fool
09:30AM  Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Sarepta Therapeutics and BioCryst Pharmaceuticals Accesswire
07:23AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : March 3, 2017
Mar-02-17 06:00PM  Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire +7.41%
04:30PM  Why Abercrombie & Fitch, W&T Offshore, and Sarepta Therapeutics Jumped Today at Motley Fool
11:41AM  Sarepta Therapeutics: What Goes Down Must Go Up at Barrons.com
11:15AM  Shark Bites: Market Taking a Break, but Probably Not for Long
10:42AM  Sarepta Therapeutics, Inc. :SRPT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
09:23AM  Morning Movers: Shake Shack Sinks, Abercrombie & Fitch Jumps, Valeant Climbs at Barrons.com
08:43AM  Coverage initiated on Sarepta Therapeutics by Instinet
Mar-01-17 04:13PM  Sarepta Stock Seesaws On 2017 Duchenne Muscular Dystrophy Guide
01:00PM  Sarepta Stock Tanks 7% on 4Q Loss at Investopedia
12:56PM  Sarepta Therapeutic shares waver amid concerns over 2017 guidance at CNBC
11:13AM  Sarepta predicts slower sales of Duchenne drug than many investors hoped at bizjournals.com
10:05AM  Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow
09:57AM  The Street Is Misreading Sarepta's Guidance
08:50AM  Edited Transcript of SRPT earnings conference call or presentation 28-Feb-17 9:30pm GMT
08:50AM  Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
07:40AM  RBC: Sarepta's Setting The Bar Low, Buy On This Weakness
Feb-28-17 07:53PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
06:46PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
04:41PM  Sarepta Therapeutics reports 4Q loss
04:30PM  Sarepta Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
04:03PM  Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments Business Wire
02:10PM  At rare disease panel, ex-FDA new drug head preaches evidence over empathy at bizjournals.com
07:07AM  Q4 2016 Sarepta Therapeutics Inc Earnings Release - After Market Close
Feb-27-17 08:42AM  Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season?
07:50AM  How the states newest Duchenne biotechs are getting a boost from patient groups at bizjournals.com
Feb-24-17 01:17PM  5 Stocks Set for Explosive Breakouts +6.20%
11:44AM  More Selling Pressure, But No Rush for the Exits
Feb-23-17 09:39AM  [2/23] This Weeks Earnings Revisions Movers
Feb-22-17 01:52PM  The Contrary Indicators Are Piling Up +5.93%
09:30AM  Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and Galectin Therapeutics Accesswire
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb-21-17 02:00PM  Did Gilead's new tool for speeding drug approval come at bargain-basement price? at bizjournals.com
11:03AM  Sarepta Sells Priority Review Voucher for $125M at Investopedia
10:09AM  Sarepta Leads Biotech Movers on Voucher Deal News
10:05AM  Sarepta sells FDA review voucher for $125M, but analyst questions price at bizjournals.com
07:28AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
07:00AM  Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M Business Wire
Feb-17-17 02:30PM  Congressman Keating calls pricy Duchenne drug an example of 'gouging' at bizjournals.com
11:11AM  3 Biotech Stocks to Buy in February at Motley Fool
07:44AM  Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
07:05AM  Santhera opens Mass. office as local Duchenne ecosystem grows at bizjournals.com
Feb-16-17 09:50AM  Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl
Feb-15-17 08:31AM  Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017 Business Wire
Feb-14-17 10:48AM  The Fed's Dilemma Is Quite Obvious
10:02AM  Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal
Feb-13-17 04:12PM  Marathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000 price at MarketWatch
Feb-10-17 12:04PM  Sarepta Muscular Dystrophy Drug Faces Competition at Investopedia -5.15%
Feb-09-17 03:51PM  FDA approves Marathon Pharma's Duchenne muscular dystrophy drug at MarketWatch
03:13PM  Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment
Feb-07-17 04:12PM  Why Sarepta Therapeutics, Inc. Stock Rose 13.2% in January at Motley Fool
Feb-02-17 10:53AM  Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys at Motley Fool
07:21AM  Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
Feb-01-17 01:28PM  Sarepta: It's Not Whether Insurers Will Pay. It's How Much They'll Pay at Barrons.com -6.31%
11:55AM  Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results
Jan-31-17 07:55PM  Catabasis shares plummet on Duchenne trial failure at bizjournals.com +7.21%
05:15PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-23-17 11:12AM  Keep Politics Out Of Science, Says Departing FDA Chief at Forbes
08:25AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : January 23, 2017
Jan-19-17 09:08AM  Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug at MarketWatch
08:40AM  Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
Jan-17-17 04:20PM  5 Healthcare Stocks Poised for Maximum Gains in 2017 at Motley Fool
02:56PM  FDA 101: What Does 'Orphan Drug Designation' Mean?
12:52PM  Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns
12:35PM  Bullish and Bearish Reversals in the Market
Jan-13-17 07:23PM  Cramer lists the stocks that you should take the cash and run on at CNBC
04:36PM  Surge From Bank Earnings Doesn't Last
Jan-12-17 10:12AM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : January 12, 2017
Jan-11-17 02:17PM  Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen at Insider Monkey -6.18%
12:25PM  Is This Going To Be Sarepta Therapeutics' Year? at Motley Fool
10:38AM  Sarepta Therapeutics: Reports of Its Demise Appear 'Greatly Exaggerated' at Barrons.com
09:46AM  Sarepta Muscular Dystrophy Drug Posts Solid Sales at Investopedia
09:30AM  Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs Accesswire
09:20AM  7 Stocks Making Big Moves With Unusual Volume
08:35AM  Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?
07:28AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : January 11, 2017
Jan-10-17 05:09PM  What Sarepta Therapeutics' CEO Said That Made the Stock Soar at Motley Fool +21.21%
03:30PM  Tuesdays Top Biopharma Movers
12:55PM  Sarepta gains $300M in value as Duchenne drug launch beats expectations at bizjournals.com
12:49PM  For Sarepta, Today's Good News Might Be Just The Beginning
11:54AM  Why Sarepta Therapeutics Has Soared 20% at Barrons.com
11:38AM  Sarepta Soars Following Encouraging Exondys 51 News
11:22AM  Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears at TheStreet
10:33AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur
10:33AM  Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; and collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDPresident, CEO & CMONov 09Option Exercise8.283,00024,84075,635Nov 10 08:19 AM
Howton David TSVP, General CounselNov 09Option Exercise23.851,00023,85022,453Nov 10 08:27 AM
Mahatme SandeshSenior Vice President, CFONov 09Option Exercise23.851,00023,85032,532Nov 10 08:26 AM
Ruff ShamimSVP, Regulatory Affairs & QualNov 08Option Exercise26.241,00026,24021,239Nov 10 08:20 AM
Mahatme SandeshSenior Vice President, CFOOct 17Option Exercise13.9030,000417,00061,532Oct 19 04:22 PM
Mahatme SandeshSenior Vice President, CFOOct 17Sale50.0830,0001,502,50231,532Oct 19 04:22 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Option Exercise13.907,311101,62327,550Sep 30 09:58 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Sale60.007,311438,66020,239Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM
Howton David TSVP, General CounselSep 19Option Exercise13.908,000111,20011,168Sep 21 09:28 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Option Exercise6.9424,352168,94189,983Sep 21 09:29 PM
Aphale JayantVP, Technical OperationsSep 19Option Exercise4.6235,000161,70036,490Sep 21 09:31 PM
Aphale JayantVP, Technical OperationsSep 19Sale50.0035,0001,750,00011,490Sep 21 09:31 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Sale50.0024,3521,217,60076,983Sep 21 09:29 PM
Howton David TSVP, General CounselSep 19Sale50.009,304465,2003,168Sep 21 09:28 PM
Kaye Edward M. MDSVP Interim CEO & CMOSep 14Sale30.0024,557736,71076,983Sep 16 04:04 PM